Compare IVVD & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVVD | SMTI |
|---|---|---|
| Founded | 2020 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.9M | 208.2M |
| IPO Year | 2021 | 2008 |
| Metric | IVVD | SMTI |
|---|---|---|
| Price | $0.53 | $33.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $8.75 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 3.3M | 227.1K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.02 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $53,426,000.00 | $15,586,976.00 |
| Revenue This Year | $61.57 | $17.31 |
| Revenue Next Year | $41.42 | $12.48 |
| P/E Ratio | ★ N/A | $681.20 |
| Revenue Growth | ★ 110.47 | 32.47 |
| 52 Week Low | $0.49 | $16.05 |
| 52 Week High | $3.07 | $35.70 |
| Indicator | IVVD | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 29.09 | 82.32 |
| Support Level | N/A | $20.47 |
| Resistance Level | $1.01 | N/A |
| Average True Range (ATR) | 0.05 | 1.26 |
| MACD | -0.01 | 0.87 |
| Stochastic Oscillator | 7.85 | 96.44 |
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.